First-generation epigenetic drugs have proven clinically useful in several hematological cancers. But newer enzyme inhibitors in the pipeline aim to be more selective and promise to broaden the portfolio of therapeutic uses.
This is a preview of subscription content, log in via an institution to check access.
References
Bostick, M. et al. Science 317, 1760–1764 (2007).
Sooryanarayana, V. Nature 419, 624–629 (2002).
Kondo, Y. et al. Nat. Genet. 40, 741–750 (2008).
Matouk, I.J. et al. PLoS ONE 2, e845 (2007).
Gupta, R.A. et al. Nature 464, 1071–1076 (2009).
Herman, D. et al. Nat. Chem. Biol. 2, 551–558 (2006).
Cui, H. et al. Science 299, 1753–1755 (2003).
Jones, J.R. et al. Am. J. Med. Genet. A. 146A, 2213–2220 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Mack, G. To selectivity and beyond. Nat Biotechnol 28, 1259–1266 (2010). https://doi.org/10.1038/nbt.1724
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.1724
- Springer Nature America, Inc.
This article is cited by
-
Inhibition of Bcl6b promotes gastric cancer by amplifying inflammation in mice
Cell Communication and Signaling (2019)
-
Epigenomic dysregulation-mediated alterations of key biological pathways and tumor immune evasion are hallmarks of gingivo-buccal oral cancer
Clinical Epigenetics (2019)
-
Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS
Scientific Reports (2017)
-
Novel SAHA analogues inhibit HDACs, induce apoptosis and modulate the expression of microRNAs in hepatocellular carcinoma
Apoptosis (2016)
-
Effects of deranged metabolism on epigenetic changes in cancer
Archives of Pharmacal Research (2015)